CalciMedica (CALC) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vyome (HIND) has outperformed CalciMedica (CALC) over the past year, losing 75.9% versus a loss of 92.3%. CalciMedica is the larger company by market cap ($8.7 million vs $8.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | HIND |
|---|---|---|
| Share price | $1.26 | $1.20 |
| Market cap | $8.69M | $8.42M |
| 1-day change | +7.69% | -17.24% |
| YTD return | -96.18% | -65.12% |
| 1-year return | -92.34% | -75.90% |
| 5-year return | — | -100.00% |
| P/E ratio (TTM) | — | 0.25 |
| EPS (TTM) | $-4.41 | $4.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $319.71K |
| Revenue growth (YoY) | — | +24.43% |
| Net income (latest FY) | $-29.56M | $-10.26M |
| Gross margin | — | 68.43% |
| Operating margin | — | -3269.35% |
| Net margin | — | -3209.75% |
| 52-week high | $36.00 | $5.88 |
| 52-week low | $1.00 | $1.20 |
| Distance from 52-week high | -96.50% | -79.59% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3868.25% | +635.83% |
| Average volume | 80.15K | 13.92K |
| Shares outstanding | 6.90M | 7.02M |
| Employees | 15 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HIND has outperformed CALC by 16.4 percentage points over the past year.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CALC vs HIND FAQ
Which is bigger, CalciMedica or Vyome?
CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.42M for Vyome (HIND).
Which stock has performed better over the past year, CALC or HIND?
HIND returned -75.90% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are CalciMedica and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.